Your browser doesn't support javascript.
loading
siRNA and targeted delivery systems in breast cancer therapy
Mirzaei, Sepideh; Abad Paskeh, Mahshid Deldar; Entezari, Maliheh; Javadian Ghaleh, Vahideh; rezaei, Shamin; Sadat Hejazi, Elahe; Kakavand, Amirabbas; Behroozaghdam, Mitra; Taheriazam, Afshin; Hashemi, Mehrdad.
Afiliação
  • Mirzaei, Sepideh; Islamic Azad University. Science and Research Branch. Faculty of Science. Tehran. Iran
  • Abad Paskeh, Mahshid Deldar; Islamic Azad University. Farhikhtegan Hospital Tehran Medical Sciences. Farhikhtegan Medical Convergence Sciences Research Center. Tehran. Iran
  • Entezari, Maliheh; Islamic Azad University. Farhikhtegan Hospital Tehran Medical Sciences. Farhikhtegan Medical Convergence Sciences Research Center. Tehran. Iran
  • Javadian Ghaleh, Vahideh; Islamic Azad University. Farhikhtegan Hospital Tehran Medical Sciences. Farhikhtegan Medical Convergence Sciences Research Center. Tehran. Iran
  • rezaei, Shamin; Islamic Azad University. Farhikhtegan Hospital Tehran Medical Sciences. Farhikhtegan Medical Convergence Sciences Research Center. Tehran. Iran
  • Sadat Hejazi, Elahe; Islamic Azad University. Farhikhtegan Hospital Tehran Medical Sciences. Farhikhtegan Medical Convergence Sciences Research Center. Tehran. Iran
  • Kakavand, Amirabbas; Islamic Azad University. Farhikhtegan Hospital Tehran Medical Sciences. Farhikhtegan Medical Convergence Sciences Research Center. Tehran. Iran
  • Behroozaghdam, Mitra; Islamic Azad University. Farhikhtegan Hospital Tehran Medical Sciences. Farhikhtegan Medical Convergence Sciences Research Center. Tehran. Iran
  • Taheriazam, Afshin; Islamic Azad University. Farhikhtegan Hospital Tehran Medical Sciences. Farhikhtegan Medical Convergence Sciences Research Center. Tehran. Iran
  • Hashemi, Mehrdad; Islamic Azad University. Farhikhtegan Hospital Tehran Medical Sciences. Farhikhtegan Medical Convergence Sciences Research Center. Tehran. Iran
Clin. transl. oncol. (Print) ; 25(5): 1167-1188, mayo 2023.
Artigo em Inglês | IBECS | ID: ibc-219505
Biblioteca responsável: ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Recently, nucleic acid drugs have been considered as promising candidates in treatment of various diseases, especially cancer. Because of developing resistance to conventional chemotherapy, use of genetic tools in cancer therapy appears inevitable. siRNA is a RNAi tool with capacity of suppressing target gene. Owing to overexpression of oncogenic factors in cancer, siRNA can be used for suppressing those pathways. This review emphasizes the function of siRNA in treatment of breast tumor. The anti-apoptotic-related genes including Bcl-2, Bcl-xL and survivin can be down-regulated by siRNA in triggering cell death in breast cancer. STAT3, STAT8, Notch1, E2F3 and NF-κB are among the factors with overexpression in breast cancer that their silencing by siRNA paves the way for impairing tumor proliferation and invasion. The oncogenic mechanisms in drug resistance development in breast tumor such as lncRNAs can be suppressed by siRNA. Furthermore, siRNA reducing P-gp activity can increase drug internalization in tumor cells. Because of siRNA degradation at bloodstream and low accumulation at tumor site, nanoplatforms have been employed for siRNA delivery to suppress breast tumor progression via improving siRNA efficacy in gene silencing. Development of biocompatible and efficient nanostructures for siRNA delivery can make milestone progress in alleviation of breast cancer patients (AU)
Assuntos

Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Neoplasias da Mama / Sistemas de Liberação de Medicamentos / RNA Interferente Pequeno / Nanopartículas Limite: Humanos Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2023 Tipo de documento: Artigo Instituição/País de afiliação: Islamic Azad University/Iran
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Neoplasias da Mama / Sistemas de Liberação de Medicamentos / RNA Interferente Pequeno / Nanopartículas Limite: Humanos Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2023 Tipo de documento: Artigo Instituição/País de afiliação: Islamic Azad University/Iran
...